Despite the superior therapeutic efficacy of mogamulizumab in CTCL, resistance to the antibody drug has emerged in many patients with MF and SS, resulting in mutations involving CCR4 [17]. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.